Clene (CLNN) Nanomedicine Provides Clinical Program Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St bounces as oil cools, inflation risks keeps Fed in focus
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for sharp weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Clene Nanomedicine Provides Clinical Program Update
February 14, 2022 7:00 AM ESTHealey ALS Platform Trial fully enrolled; top-line data expected 2H 2022Significant survival benefit from RESCUE-ALS open label extension (OLE) Phase 2 trial to be presented at upcoming Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Nashville, TN March 13-16, 2022VISIONARY-MS to conclude early due to COVID pandemic-related challenges. Unblinded data expected 2H 2022; insights to inform new Phase 2/3 MS trial. REPAIR-MS Phase 2 Trial initiates second cohort to confirm target engagement in non-active progressive MS COVID-19 Phase 2 trial completes... More
